 VolitionRx NYSE-A:VNRX said it ended third-quarter 2022 with US16.4 million in cash and cash equivalents, thanks to careful management of expenditures with net cash used in operating activities averaging approximately 2.3 million per month in the quarter. Cash equivalents was down slightly from 16.7 million at the quarter ended June 30, 2022, the Henderson, Nevada-based company said. 